Skip to content

Temporary Artery Clipping for Robotically-assisted Myomectomy, a Multicentric Randomized Controlled Trial

Temporary Artery Clipping for Robotically-assisted Myomectomy, a Multicentric Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06269809
Acronym
TACROM
Enrollment
82
Registered
2024-02-21
Start date
2023-05-04
Completion date
2025-05-30
Last updated
2025-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fibroid Uterus

Keywords

myomectomy, fibroid, myoma, blood loss, temporary artery clipping, hemostatic measures

Brief summary

This study aims to investigate the efficacy of temporary clipping of the uterine artery and utero-ovarian ligament during robotically assisted myomectomy (RAM) for uterine fibroids. While RAM is increasingly used for myomectomy, bleeding control remains challenging. Temporary clipping of arteries has shown promise in conventional laparoscopy but has not been studied in RAM. This randomized controlled trial will assess primary endpoints such as estimated blood loss, need for transfusion, and hemoglobin drop, alongside secondary outcomes like complication rates and operation time.

Detailed description

Uterine fibroids, also known as myomas or leiomyomas, are benign smooth muscle neoplasms of the uterus. Uterine fibroids are the most common neoplasms affecting women of reproductive age (up to 70-80% at the age of 50)(1). As fibroids grow, they may induce clinical problems such as menorrhagia, abdominal pain, or infertility.(2,3) Removal of uterine fibroids (myomectomy) is a gynaecological surgical procedure performed most frequently through laparotomy or minimally invasive surgery such as conventional laparoscopic or robotically assisted surgery. Because of the straight-stick instruments with limited degree of freedom, the excision and suturing of the myoma can be rather cumbersome, not in the least because myomectomies may be associated with relatively profuse peri-operative bloodloss. Owing to its enhanced 3D vision and wristed instruments, robotically assisted surgery may be a more suitable surgical technique, especially in the case of multiple myomas, large myomas or posterior localization. Consequently, in recent years a gradual shift has been seen to the use of robotically assisted myomectomies. However, control of the bleeding during a myomectomy can be a challenge, even in the hands of an experienced robotic surgeon. Various strategies have been developed to combat this scenario; including rectal or IV misoprostol, intramyometrial injection of bupivacaine with epinephrine or vasopressin, , tranexaminic acid IV or various ligation strategies. There is moderate quality evidence for some of these interventions. Recently, the use of clips to temporary occlude the uterine artery for myomectomy with conventional laparoscopy for prevention of blood loss was validated in several studies, including 2 randomized controlled trials. To enhance hemostasis, recent articles described a technique to temporary clip both the uterine artery and infundibulopelvic artery with conventional laparoscopy, also resulting in fewer intra-operative bleeding compared to no artery clipping. The possible benefit of these ligation technique has never been studied in the setting of robotically-assisted myomectomies. On the one hand, RAM may involve more complex cases due to myoma size, localization or multiple myomas, and on the other hand, bleeding control may also be better with robotic surgery. This makes a prediction of the usefulness of this technique difficult, in terms of reducing blood loss. Estimated blood loss remains a difficult outcome to reliably quantify, especially when using only visual parameters. During RAM, often only suction is used, making the estimation easier in comparison to open surgery, for which a variety of compresses and suction is used. This study will work with multiple primary endpoints, combining estimated blood loss over 500 mL, the need for a peri-operative blood transfusion or a hemoglobin drop exceeding 2 g/dL. Other secondary outcomes will include complication rate, the operation time, postoperative pain and the need for additional hemostatic measures. In the literature, the risk of changes in ovarian reserve is also investigated, however it proved not significant and this was only a theoretical risk in the context of temporary clipping the infundibulopelvic artery, which is the main blood supply of the ovary. In this study, which will involve temporary clipping the utero-ovarian ligmant, there is no risk for a decrease in ovarian reserve.

Interventions

PROCEDURETemporary clipping of the uterine arteries and the utero-ovarian ligmants.

Temporary clipping of the uterine arteries and the utero-ovarian ligaments using laparoscopic clips/bulldog clamps, during robotically assisted myomectomy.

PROCEDURENo temporary clipping of the uterine arteries and the utero-ovarian ligmants.

Robotically assisted myomectomy, for which no temporary clipping of the uterine arteries and the utero-ovarian ligaments

Sponsors

Amsterdam UMC, location VUmc
CollaboratorOTHER
Bichat Hospital
CollaboratorOTHER
Rennes University Hospital
CollaboratorOTHER
Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Multicentric non-blinded randomized controlled trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Participants eligible for inclusion in this Trial must meet all of the following criteria: 1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures 2. Use of highly effective methods of birth control; defined as those that, alone or in combination, result in low failure rate (i.e., less than 1% per year) when used consistently and correctly; such as implants, injectables, combined oral contraceptives, some IUDs, true sexual abstinence (i.e. refraining from heterosexual intercourse during the entire period of risk associated with the Trial treatment(s)) or commitment to a vasectomised partner. 3. Female 4. Age: 18-50 years 5. Myomas, eligible for myomectomy, with the exclusion of FIGO 7-8 myomas.

Exclusion criteria

Participants eligible for this Trial must not meet any of the following criteria: 1. Any disorder, which in the Investigator's opinion might jeopardise the participant's safety or compliance with the protocol 2. Any prior or concomitant treatment(s) that might jeopardise the participant's safety or that would compromise the integrity of the Trial 3. Participation in an interventional Trial with an investigational medicinal product (IMP) or device 4. Patient refusal to participate in the Trial 5. (Possible) malignancy 6. any contra indication for a laparoscopic or robotic surgery

Design outcomes

Primary

MeasureTime frameDescription
Peri-operative blood loss: Estimated blood loss1 weekMultiple primary endpoints will be used to asses the blood loss: \- Estimated blood loss \>500 mL
Peri-operative blood loss: Hemoglobin drop perioperatively >2g/dL1 dayMultiple primary endpoints will be used to asses the blood loss: \- Hemoglobin drop perioperatively \>2g/dL (difference between hemoglobin preoperatively and postoperatively)
Peri-operative blood loss: Need for peri-operative blood transfusion1 weekMultiple primary endpoints will be used to asses the blood loss: \- Need for peri-operative blood transfusion

Secondary

MeasureTime frameDescription
Hospitalisation time6 weeksNumber of postoperative nights the patient had to stay in the hospital.
Number of patients requiring secondary hemostatic measures1 dayWas there a need for non-routine hemostatic measures, such as: * Tranexamic acid * Misoprostol * Oxytocin * Embolisation * Local application of sealant patch or glue (e.g TachoSil or Tisseel) * Hysterectomy
Operation time in minutes1 dayTotal surgical time, from the completion of anesthesia induction untill the end of surgery (in minutes)
Number of patients with complications postoperatively, graded by Clavien Dindo classification6 weeksThe Clavien Dindo classification is a validated tool to quantitatively assess postoperative complications. Grade 0: No complications Grade 1: Any deviation from normal postoperative course, without requiring intervention Grade 2: Requiring pharmacological treatment Grade 3: Requiring surgical, endoscopic or radiological intervention Grade 4: Life-treathening complication requiring intermediate or intensive care Grade 5: Death of a patient

Countries

Belgium, France, Netherlands

Contacts

Primary ContactStefan Timmerman, MD
stefan.timmerman@uzleuven.be+3216348826
Backup ContactWouter Froyman, MD, PhD
wouter.froyman@uzleuven.be+3216344202

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026